CN112442095B - Refining method of vitamin B12 and application of obtained product - Google Patents
Refining method of vitamin B12 and application of obtained product Download PDFInfo
- Publication number
- CN112442095B CN112442095B CN202011400144.8A CN202011400144A CN112442095B CN 112442095 B CN112442095 B CN 112442095B CN 202011400144 A CN202011400144 A CN 202011400144A CN 112442095 B CN112442095 B CN 112442095B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- pure
- refining method
- refining
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 title claims abstract description 66
- 229930003779 Vitamin B12 Natural products 0.000 title claims abstract description 65
- 235000019163 vitamin B12 Nutrition 0.000 title claims abstract description 65
- 239000011715 vitamin B12 Substances 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000007670 refining Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 7
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 230000002195 synergetic effect Effects 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 239000000047 product Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- GJLPUBMCTFOXHD-UPHRSURJSA-N (11z)-1$l^{2},2$l^{2},3$l^{2},4$l^{2},5$l^{2},6$l^{2},7$l^{2},8$l^{2},9$l^{2},10$l^{2}-decaboracyclododec-11-ene Chemical class [B]1[B][B][B][B][B]\C=C/[B][B][B][B]1 GJLPUBMCTFOXHD-UPHRSURJSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 5
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical group [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 5
- 239000012043 crude product Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 210000004027 cell Anatomy 0.000 abstract description 16
- 210000004881 tumor cell Anatomy 0.000 abstract description 13
- 230000036039 immunity Effects 0.000 abstract description 2
- 229910052796 boron Inorganic materials 0.000 description 20
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- -1 polycyclic compound Chemical class 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 5
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 5
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 2
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000001637 plasma atomic emission spectroscopy Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- ZUXWRGYAUISHCH-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;boron Chemical compound [B].OC(=O)[C@@H](N)CC1=CC=CC=C1 ZUXWRGYAUISHCH-QRPNPIFTSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000005385 Intramolecular Transferases Human genes 0.000 description 1
- 108010031311 Intramolecular Transferases Proteins 0.000 description 1
- 102000019010 Methylmalonyl-CoA Mutase Human genes 0.000 description 1
- 108010051862 Methylmalonyl-CoA mutase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- MZFOKIKEPGUZEN-FBMOWMAESA-N methylmalonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MZFOKIKEPGUZEN-FBMOWMAESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
- A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a refining method of vitamin B12. The invention relates to a refining method of vitamin B12, which comprises the following steps: mixing the crude vitamin B12 with an organic solvent, cooling to 0-5 ℃, adding a reducing agent, stirring at room temperature for 1-2 hours, filtering, and drying at 40-60 ℃ in vacuum to obtain a refined pure vitamin B12 product, wherein the purity of the pure vitamin B12 product is more than 99%. The vitamin B12 is creatively used as the BNCT medicament auxiliary medicament, the enrichment effect of the BNCT medicament in tumor cells is more obvious through synergistic use, and meanwhile, the vitamin B12 has the effects of protecting cells, improving the immunity of organisms and the like.
Description
Technical Field
The invention relates to the technical field of chemistry, in particular to a refining method of vitamin B12 and application of a product obtained by the method.
Background
Vitamin B12, also called cobalamin, is a polycyclic compound containing 3-valent cobalt, and 4 reduced pyrrole rings are linked together to become 1 corrin macrocycle (similar to porphyrin), which is the only vitamin containing metal elements. The vitamin B12 is red crystal powder, has no smell and taste, is slightly soluble in water and ethanol, is most stable under the condition of pH 4.5-5.0 and weak acid, and can be decomposed in strong acid (pH <2) or alkaline solution to a certain extent when being heated. Higher animals and plants cannot produce vitamin B12, and vitamin B12 in nature is synthesized by microorganisms. Vitamin B12 is the only vitamin that needs the help of intestinal secretions (endogenous factors) to be absorbed, and is involved in the production of bone marrow red blood cells, prevention of pernicious anemia, and prevention of damage to the cerebral nerves. The physiological effects include the following: b12 is known to be a coenzyme for several mutases, such as methylaspartic mutase, which catalyzes the conversion of Glu to methyl Asp, methylmalonyl CoA mutase, which catalyzes the conversion of methylmalonyl CoA to succinyl CoA. The B12 coenzyme is also involved in the transfer of methyl and other one-carbon units. B12 mainly exists in meat, soybean and some herbs in plants also contain B12, intestinal bacteria can be synthesized, so that the B12 is not deficient in general, but B12 is a vitamin which is easy to be deficient by digestive tract disease patients and is an essential element indispensable for erythropoiesis, and if the B12 is seriously deficient, pernicious anemia can be caused. Vitamin B12 is widely present in animal food. And the form cannot be absorbed by human body. In addition, vitamin B12 is also the only vitamin containing essential minerals, and is red due to cobalt, also known as red vitamin, which is a few colored vitamins. Although vitamin B12 belongs to B group vitamin, it can be stored in liver, and its deficiency symptoms can only appear after more than half a year. The vitamin B12 is required in a small amount and is not deficient as long as the diet is normal. A small number of people with poor absorption need special attention.
Boron Neutron Capture Therapy (Boron Neutron Capture Therapy) is abbreviated as BNCT, namely is applied to thermal Neutron irradiation to target Boron gathered at tumor or cancer parts, and heavy particle alpha particles (helium nuclei) and high-energy Li nuclei are generated after the Boron captures neutrons so as to selectively kill tumor and cancer cells.
The vitamin B12 as BNCT type drug adjuvant is not reported in the literature, and is a great breakthrough if reasonable use can be realized. Meanwhile, since crude vitamin B12 has many impurities due to a complicated preparation process and cannot be directly applied, a refining method thereof needs to be studied.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a refining method of vitamin B12, and the pure vitamin B12 obtained by the method can be used as BNCT type medicine auxiliary medicines. The effect of high concentration enrichment of boron ions in tumor cells is enhanced.
The technical scheme is as follows: the invention relates to a refining method of vitamin B12, which comprises the following steps: mixing the crude vitamin B12 product with an organic solvent, cooling to 0-5 ℃, adding a reducing agent, stirring at room temperature for 1-2 hours, filtering, and drying at 40-60 ℃ in vacuum to obtain a refined vitamin B12 pure product, wherein the purity of the pure vitamin B12 product is more than 99%.
Specifically, the organic solvent is: methanol and ethanol.
Specifically, the reducing agent is sodium cyanoborohydride.
Specifically, the addition amount of the reducing agent is 10-15% of the mass of the crude vitamin B12.
The purity of the vitamin B12 pure product obtained by the method is within the range of 99.4-99.7%.
Furthermore, the invention also provides the application of the refining method of the vitamin B12, and the pure product of the vitamin B12 obtained by the method of the invention and the o-carborane derivative have synergistic effect to increase the selectivity of the tumor cells to boron ions, thereby enhancing the effect of high-concentration enrichment of the boron ions in the tumor cells.
Specifically, the structure of the o-carborane derivative is as follows:
specifically, the mass ratio of the pure vitamin B12 to the o-carborane derivative is as follows: 1: 10-12. Preferably 1: 10.
Further, the resulting application may ultimately inhibit tumor cells, or kill tumor cells by irradiation with external atomic energy.
Has the advantages that: the vitamin B12 is creatively used as the BNCT medicament auxiliary medicament, the enrichment effect of the BNCT medicament in tumor cells is more obvious through synergistic use, and meanwhile, the vitamin B12 has the effects of protecting cells, improving the immunity of organisms and the like.
Drawings
FIG. 1 is a liquid chromatogram of vitamin B12 crude product
FIG. 2 is a liquid chromatogram of a pure vitamin B12 product obtained in example 1
FIG. 3 is a liquid chromatogram of pure vitamin B12 obtained in example 2
FIG. 4 is a liquid chromatogram of a blank experiment of vitamin B12 obtained in example 3
Detailed Description
The following examples illustrate the invention in more detail, but the scope of the invention is not limited to the examples.
Example 1
Adding 10 g of crude vitamin B12 (with the content of 96.512%) and 100 g of methanol into a 500 ml round-bottom flask, cooling to 0-5 ℃, adding 1 g of sodium cyanoborohydride for 3 times, stirring at room temperature for 1 hour, filtering, and vacuum-drying at 50 ℃ for 12 hours to obtain 8.6 g of pure vitamin B12, wherein the yield of the pure vitamin B12 is 86%; the purity is greater than 99.674%. The chromatogram is shown in FIG. 2, and the data are shown in the following table
Detector A214nm
| Peak# | Ret.Time | Area | Height | Area% | Conc. | Unit |
| 1 | 3.600 | 44751 | 5051 | 0.180 | 0.180 | |
| 2 | 3.876 | 3081 | 414 | 0.019 | 0.019 | |
| 3 | 4.226 | 15886874 | 1606650 | 99.674 | 99.674 | |
| 4 | 6.080 | 4291 | 385 | 0.027 | 0.027 | |
| 5 | 6.863 | 3605 | 287 | 0.023 | 0.023 | |
| 6 | 7.361 | 1221 | 95 | 0.008 | 0.008 | |
| 7 | 19.341 | 10634 | 434 | 0.067 | 0.067 | |
| 8 | 22.669 | 10720 | 467 | 0.067 | 0.067 | |
| 9 | 22.875 | 3862 | 352 | 0.024 | 0.024 | |
| 10 | 24.247 | 2392 | 182 | 0.015 | 0.015 | |
| 11 | 24.492 | 1081 | 159 | 0.007 | 0.007 | |
| Total of | 15972511 | 1614477 | 100.000 |
Example 2
Adding 10 g of crude vitamin B12 (with the content of 96.512%) and 100 g of ethanol into a 500 ml round-bottom flask, cooling to 0-5 ℃, adding 1 g of sodium cyanoborohydride for 3 times, stirring at room temperature for 2 hours, filtering, and vacuum-drying at 50 ℃ for 12 hours to obtain a pure vitamin B12 product with the yield of 8.9 g of 89%; the purity is greater than 99.464%. The chromatogram is shown in FIG. 3, and the data are shown in the following table
Detector A214nm
| Peak# | Ret.Time | Area | Height | Area% | Conc. | Unit |
| 1 | 3.600 | 44751 | 5051 | 0.280 | 0.280 | |
| 2 | 3.876 | 3081 | 414 | 0.019 | 0.019 | |
| 3 | 4.226 | 15886874 | 1606650 | 99.464 | 99.464 | |
| 4 | 6.080 | 4291 | 385 | 0.027 | 0.027 | |
| 5 | 6.863 | 3605 | 287 | 0.023 | 0.023 | |
| 6 | 7.361 | 1221 | 95 | 0.008 | 0.008 | |
| 7 | 19.341 | 10634 | 434 | 0.067 | 0.067 | |
| 8 | 22.669 | 10720 | 467 | 0.067 | 0.067 | |
| 9 | 22.875 | 3862 | 352 | 0.024 | 0.024 | |
| 10 | 24.247 | 2392 | 182 | 0.015 | 0.015 | |
| 11 | 24.492 | 1081 | 159 | 0.007 | 0.007 | |
| Total of | 15972511 | 1614477 | 100.000 |
Example 3
(blank experiment without adding sodium cyanoborohydride) 10 g of crude vitamin B12 (content 96.512%) and 100 g of ethanol are added into a 500 ml round-bottom flask, the temperature is reduced to 0-5 ℃, the mixture is stirred for 2 hours at room temperature, filtered and dried in vacuum at 50 ℃ for 12 hours to obtain a pure vitamin B12 product with the yield of 9.9 g and 99 percent; the purity was 96.912%. The chromatogram is shown in FIG. 4, and the data are shown in the following table
Detector A214nm
| Peak# | Ret.Time | Area | Height | Area% | Conc. | Unit |
| 1 | 2.978 | 71287 | 5899 | 0.313 | 0.313 | |
| 2 | 3.607 | 202610 | 22760 | 1.431 | 1.431 | |
| 3 | 4.228 | 13668896 | 1410020 | 96.912 | 96.912 | |
| 4 | 7.237 | 5171 | 332 | 0.037 | 0.037 | |
| 5 | 16.184 | 148841 | 2561 | 1.051 | 1.051 | |
| 6 | 19.283 | 7422 | 285 | 0.052 | 0.052 | |
| 7 | 22.698 | 43870 | 1228 | 0.310 | 0.310 | |
| 8 | 24.200 | 14838 | 452 | 0.105 | 0.105 | |
| Total of | 14162934 | 1443537 | 100.000 |
Example 4
The test result of the in vitro cell activity of the o-carborane derivative and the vitamin B12 is shown.
The structure of the o-carborane derivative is as follows:
the determination of the related performance indexes of the compounds is a common method in the field.
1. Determination of IC50
At different sample concentrations, after 48h of administration, the growth inhibition of the compound on colon tumor cells CT26 was examined by the general MTT method, and finally IC50 was calculated so that the drug concentration required to inhibit cell survival was determined from half the lethal dose, and the results represent the average ±). .
MTT is tetramethyl azoazolium salt, which is a yellow dye capable of accepting hydrogen ions. Succinate dehydrogenase (succinate dehydrogenase) and cytochrome c (cytochromec) in mitochondria of living cells can crystallize blue-purple formazan (formazan) to precipitate MTT, and dead cells do not have this function. After the resulting formazan crystals were dissolved in dimethyl sulfoxide (DMSO), their absorbance at 490nM or 570nM was measured by an enzyme linked immunosorbent assay to monitor formazan production. Since formazan crystals are produced in an amount proportional to the number of living cells, the effect of the drug on the cell viability can be detected. The method is widely used for screening and testing the antitumor drugs due to the characteristics of high sensitivity, economy and the like.
The specific experimental method is as follows: various cells are prepared into 5 multiplied by 10 after centrifugation3Adding 100 mu L of cell suspension into each well of a 96-well plate, sucking out original culture solution after culturing for 24h conventionally, adding 200 mu L of prepared compound I, II or Boron Phenylalanine (BPA) samples, 5 concentrations of compound I and vitamin B12 and compound II and vitamin B12, wherein the final concentration of each sample is 0.137 mu M, 0.046 mu M, 1.235 mu M, 0.412 mu M and 3.704 mu M, each concentration is 4 multiple wells, wells around the 96-well plate are sealed by PBS, a negative control group and a blank control group are reserved, 20 mu L of MTT solution is added into each well after the compound acts for 72h, culturing is continued for 4h, carefully sucking away the culture medium in the wells, adding 150 mu L of DMSO, shaking for 10min, measuring the OD value of each well at 490nM of a microplate reader, and calculating the inhibition rate of the samples at different concentrations according to the following formula: the inhibition ratio (control well OD value-dosing well OD value)/control well OD value × 100%. Finally, the IC50 value of the sample was calculated using the relevant software.
The operation method comprises the following steps:
(1) colon tumor CT26 cell (5X 10)5Individual cells) were cultured aerobically and anaerobically in 96-well plates. Under the aerobic culture condition of 36.5-37 ℃, providing sterile deionized oxygen at the oxygen supply speed of 0.3 cm/minute2And sufficient administration time was 12 hours. The anaerobic culture condition is 36.5-37 ℃, the condition of a sterile anaerobic sealed drying oven is adopted, and the sufficient time is 12 hours.
(2) The o-carborane compounds I, II, compound I with vitamin B12, compound II with vitamin B12 and Borophenylalanine (BPA) were treated sequentially (3mM to 1mM) for 72 hours.
(3) Sequentially adding 3- (4, 5-dimethylthiazole-2) -2, 5-diphenyl tetrazolium bromide salt solution, and culturing for 4 hours.
(4) Shaking was performed after dilution with 150. mu.L of dimethyl sulfoxide.
(5) The protein content is determined by an enzyme linked immunosorbent assay device at 595 nm.
2. Boron absorption
P-35 cells (5X 10)3Cells) were treated in the presence of compounds I, II and Borophenylalanine (BPA) (uniform boron concentration of 10.8ppm) for 3 hours. Washing with 3 drops of phosphate buffer solution for three times;
(4) perchloric/peroxy acids were analyzed.
(5) Aerobic and anaerobic cultures were performed at 70 ℃. Under the aerobic culture condition of 36.5-37 ℃, sterile deionized oxygen is provided, and the oxygen supply speed is per minute/0.3 cm2And sufficient time was given at 12 hours. The anaerobic culture condition is 36.5-37 ℃, the condition of a sterile anaerobic sealed drying oven is adopted, and the sufficient time is 12 hours.
(6) Plasma emission spectrometry testing.
The operation method comprises the following steps:
(1) colon tumor CT26 cell (5X 10)5Individual cells) were cultured aerobically and anaerobically in p-35 cell dishes. Under the aerobic culture condition of 36.5-37 ℃, sterile deionized oxygen is provided, and the oxygen supply speed is per minute/0.3 cm2And sufficient time was given at 12 hours. The anaerobic culture condition is 36.5-37 ℃, and the time is fully 12 hours under the condition of an aseptic anaerobic sealed drying oven.
(2) The o-carborane derivatives I and II, the compound I and the vitamin B12, and the compound II and the vitamin B12 are treated for 3 hours in sequence (the boron concentration is 10.8 ppm).
(3) And washed three more times with 3 drops of phosphate buffered saline.
(4) The activity assay was then performed with perchloric/peroxyacids.
(5) Aerobic and anaerobic cultures were performed at 70 ℃. Under the aerobic culture condition of 36.5-37 ℃, sterile deionized oxygen is provided, and the oxygen supply speed is per minute/0.3 cm2And sufficient time was given at 12 hours. Anaerobic cultureThe conditions are 36.5-37 ℃, and the time is 12 hours under the conditions of an aseptic oxygen-free sealed drying oven.
(6) Plasma emission spectrometry testing.
The following table: IC50 and boron accumulation concentration Table for various Compounds
As a result, the IC50 activities of BPA were 6.43X 10, respectively-5(+/-0.22) and the aggregation concentration of boron is 0.083 +/-0.012 ppm, while the designed compounds I and II reach the high aggregation concentration which is 8-10 times that of BPA, and the IC50 activity of the compound I is 1.10 multiplied by 10 respectively-5(± 0.22); the boron concentration is 0.682 +/-0.42 ppm respectively; the IC50 activities of the compound II were 1.89X 10-5(± 0.73); the boron concentration was 0.754. + -. 0.43ppm, respectively, and the aggregation effect of the original design was sufficiently obtained. However, the IC50 activity of the compound I after addition of vitamin B12 was 1.21X 10-5(± 0.13); the boron concentration is 0.814 plus or minus 0.21ppm respectively; the IC50 activity of compound II was 1.94X 10-5(± 0.58); the boron concentration is 0.912 +/-0.32 ppm, the inhibition activity of tumor cells and tumor cells becomes more prominent, and the inhibition effect is increased by 1-3 times. The self structure of the borane medicament has certain inhibitory activity through in vitro experiments, the concentration of boron in cells is increased by additionally introducing borane, and the novel structure ensures that boron ions are easier to gather in tumor cells to achieve a high boron gathering effect. After high boron is gathered in the tumor cells, the tumor cells are selectively killed by irradiation of external atomic energy to generate heavy-particle alpha particles (helium nuclei) and high-energy Li nuclei.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application.
Claims (5)
1. A refining method of vitamin B12 is characterized by mixing a vitamin B12 crude product with an organic solvent, cooling to 0-5 ℃, adding a reducing agent, stirring at room temperature for 1-2 hours, filtering, and drying at 40-60 ℃ in vacuum to obtain a refined vitamin B12 pure product, wherein the purity of the vitamin B12 pure product is more than 99%; the reducing agent is sodium cyanoborohydride; the crude purity was 96.512%.
2. The method for refining vitamin B12, according to claim 1, wherein the organic solvent is: methanol and ethanol.
3. The method for refining vitamin B12 according to claim 1, wherein the addition amount of the reducing agent is 10-15% of the weight of crude vitamin B12.
4. The use of the refining method of vitamin B12 according to claim 1, wherein the use comprises preparing pure vitamin B12 by the refining method of claim 1, and using the pure vitamin B12 and the orthocarborane derivative as BNCT type auxiliary drugs in a synergistic effect;
the structure of the o-carborane derivative is as follows:
5. the use of the refining method of vitamin B12 according to claim 4, wherein the mass ratio of the pure vitamin B12 to the o-carborane derivative is as follows: 1: 10-12.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011400144.8A CN112442095B (en) | 2020-12-01 | 2020-12-01 | Refining method of vitamin B12 and application of obtained product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011400144.8A CN112442095B (en) | 2020-12-01 | 2020-12-01 | Refining method of vitamin B12 and application of obtained product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112442095A CN112442095A (en) | 2021-03-05 |
| CN112442095B true CN112442095B (en) | 2022-07-22 |
Family
ID=74739548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011400144.8A Active CN112442095B (en) | 2020-12-01 | 2020-12-01 | Refining method of vitamin B12 and application of obtained product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112442095B (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000045857A2 (en) * | 1999-02-01 | 2000-08-10 | Schering Aktiengesellschaft | Metal macrocycles for two-step forms of radiotherapy |
| WO2000062808A2 (en) * | 1999-04-16 | 2000-10-26 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as antitumor agents |
| CN1524086A (en) * | 2001-06-05 | 2004-08-25 | ������������ʽ���� | Process for producing methylcobalamin |
| CN1620289A (en) * | 2001-06-06 | 2005-05-25 | 布鲁克黑文科学联合会 | Novel metalloporphyrins and their uses as radiosensitizers for radiation therapy |
| CN101268085A (en) * | 2005-08-19 | 2008-09-17 | 海默尔凯普股份公司 | Boron Compounds for Boron Neutron Capture Therapy |
| CN102977173A (en) * | 2012-12-13 | 2013-03-20 | 上海华震科技有限公司 | Purifying process of high-purity vitamin B12 |
| CN106279231A (en) * | 2016-08-24 | 2017-01-04 | 南京江原安迪科正电子研究发展有限公司 | Boron-containing compound for BNCT and its production and use |
| MX2016006530A (en) * | 2016-05-19 | 2017-11-20 | Interquim S A De C V | Process for transforming methylcobalamin into cyanocobalamin. |
| CN109928999A (en) * | 2019-04-08 | 2019-06-25 | 童永彭 | The preparation method and application of boron-containing compound, pharmaceutical composition and boron-containing compound |
| CN111217846A (en) * | 2020-04-20 | 2020-06-02 | 南京艾斯特医药科技有限公司 | O-carborane derivative, and synthesis method and application thereof |
-
2020
- 2020-12-01 CN CN202011400144.8A patent/CN112442095B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000045857A2 (en) * | 1999-02-01 | 2000-08-10 | Schering Aktiengesellschaft | Metal macrocycles for two-step forms of radiotherapy |
| WO2000062808A2 (en) * | 1999-04-16 | 2000-10-26 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as antitumor agents |
| CN1524086A (en) * | 2001-06-05 | 2004-08-25 | ������������ʽ���� | Process for producing methylcobalamin |
| CN1620289A (en) * | 2001-06-06 | 2005-05-25 | 布鲁克黑文科学联合会 | Novel metalloporphyrins and their uses as radiosensitizers for radiation therapy |
| CN101268085A (en) * | 2005-08-19 | 2008-09-17 | 海默尔凯普股份公司 | Boron Compounds for Boron Neutron Capture Therapy |
| CN102977173A (en) * | 2012-12-13 | 2013-03-20 | 上海华震科技有限公司 | Purifying process of high-purity vitamin B12 |
| MX2016006530A (en) * | 2016-05-19 | 2017-11-20 | Interquim S A De C V | Process for transforming methylcobalamin into cyanocobalamin. |
| CN106279231A (en) * | 2016-08-24 | 2017-01-04 | 南京江原安迪科正电子研究发展有限公司 | Boron-containing compound for BNCT and its production and use |
| CN109928999A (en) * | 2019-04-08 | 2019-06-25 | 童永彭 | The preparation method and application of boron-containing compound, pharmaceutical composition and boron-containing compound |
| CN111217846A (en) * | 2020-04-20 | 2020-06-02 | 南京艾斯特医药科技有限公司 | O-carborane derivative, and synthesis method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| Synthesis and Characterization of nido-Carborane-Cobalamin Conjugates;Harry P. C. Hogenkamp et al.;《Nuclear Medicine & Biology》;20001231;第17卷;第89-92页 * |
| Vitamin B12: chemical modifications;Keith ó Proinsias t al.;《Chemical Society Reviews》;20130529;第42卷;第6605-6619页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112442095A (en) | 2021-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2253379T3 (en) | USE OF EXTRACTS OF SpermATOFITOS AS MODULATORS OF THE IMMUNE RESPONSE. | |
| US11884695B2 (en) | Heavy vitamin B12 derivatives | |
| WO2021169744A1 (en) | Fluorescent carbon quantum dot, and preparation method therefor and application thereof in preparation of antitumor drug sensitizer | |
| CN111893096B (en) | Method for preparing genitourinary system tumor cell iron death model based on ferric ammonium citrate and application of prepared antitumor drug | |
| CN101234951B (en) | Biphenyl compounds and their preparation methods and applications | |
| CN112442095B (en) | Refining method of vitamin B12 and application of obtained product | |
| CN107893090B (en) | Application of fermentation compound of aspergillus terreus H768 in preparation of antiallergic drugs | |
| KR101308539B1 (en) | novel compounds Fusarisetins and uses thereof | |
| CN110818728B (en) | Preparation method and use of polythiodiketopiperazine compound Secoemestrin C | |
| CN113908180B (en) | Application of nano-selenium cordyceps militaris aqueous extract in reducing radiotherapy injury and protective agent thereof | |
| CN104327147A (en) | Ergosterol-typed compound, preparation method and application thereof | |
| CN115181083B (en) | Preparation method of compound Cyophiobiolins A-B and its application in preparing anti-inflammatory drugs | |
| CN109081842B (en) | Deep-sea fungus-derived anthraquinone compound and application thereof in preparation of antiallergic drugs | |
| CN111217878B (en) | Andrastone compounds, preparation method thereof and application thereof in preparing antiallergic drugs | |
| CN109705183B (en) | Smelly seven secondary metabolites and pharmaceutical compositions thereof, preparation method and application thereof | |
| CN102051394A (en) | Preparation method and application of sulfo-diketopiperazine compounds | |
| CN112494649A (en) | O-carborane compound composition for assisting BNCT | |
| CN112480157B (en) | O-carborane derivative for assisting BNCT and synthetic method thereof | |
| CN115227691B (en) | Application of lactone compound from aspergillus flavus in anti-human breast cancer medicine | |
| CN112661779B (en) | Biosynthesis method and application of N-methyl o-carborane-L-propionamide | |
| EP4317158A1 (en) | Quinone compound and pharmaceutical use thereof | |
| CN109251224A (en) | There is chemotherapy and the complex of iridium of phototherapy antitumor action and its preparation method and application simultaneously | |
| CN112920241B (en) | Benzimidazole derivative BI308 and preparation method and application thereof | |
| CN1172914C (en) | Glutarimide compound S632A3, its preparation method and its application in the preparation of drugs for the treatment of viral infections and tumors | |
| CN113368090B (en) | Use of 3,4-secocycloartane-type tetracyclic triterpene compounds or pharmaceutically acceptable salts thereof in the preparation of anticancer drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220630 Address after: 200000 room 131, No. 14, Lane 2165, Wangyuan Road, Fengxian District, Shanghai Applicant after: SHANGHAI KEDAI BIO-TECH Co.,Ltd. Address before: Room 116, building 10, Xiezhong Yaju, 618 longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province Applicant before: Nanjing Astor Pharmaceutical Technology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |